Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio RosenstockJan MarquardLori M B LaffelDietmar NeubacherStefan KaspersDavid Z I CherneyBernard ZinmanJay S SkylerJyothis GeorgeNima SoleymanlouBruce A PerkinsPublished in: Diabetes care (2018)
Empagliflozin improved glycemic control and weight in T1D without increasing hypoglycemia. Ketoacidosis rate was comparable between empagliflozin 2.5 mg and placebo but increased with 10 mg and 25 mg. Ketone monitoring for early ketoacidosis detection and intervention and lower empagliflozin doses may help to reduce this risk.